In the last trading session, 31.36 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) were traded, and its beta was 0.97. Most recently the company’s share price was $4.16, and it changed around -$0.6 or -12.62% from the last close, which brings the market valuation of the company to $1.67B. RXRX currently trades at a discount to its 52-week high of $12.36, offering almost -197.12% off that amount. The share price’s 52-week low was $3.79, which indicates that the current value has risen by an impressive 8.89% since then.
Recursion Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.43. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 6 recommended RXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Recursion Pharmaceuticals Inc is expected to report earnings per share of -0.34 for the current quarter.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has showed a red trend with a performance of -12.62% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.90 on recent trading dayincreased the stock’s daily price by 29.49%. The company’s shares are currently down -38.54% year-to-date, but still down -27.36% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -2.00% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 30.67% from its current value. Analyst projections state that RXRX is forecast to be at a low of $6 and a high of $6.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
The year-over-year growth rate is expected to be 28.84%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 16.25M in revenue for the current quarter. 6 analysts expect Recursion Pharmaceuticals Inc to make 20.48M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 14.42M and 26.08M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 12.71%. Forecasts for the next quarter put sales growth at -21.47%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.28%. Recursion Pharmaceuticals Inc earnings are expected to increase by 3.99% in 2025, but the outlook is positive 19.85% per year for the next five years.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in June.
BAILLIE GIFFORD & CO, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 19.28 shares worth $80.12 million, making up 4.83% of all outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held roughly 12.61 shares worth around $52.38 million, which represents about 3.15% of the total shares outstanding.
